Abstract
The study investigated the role of genetic polymorphisms in four genes of the calcineurin pathway on cardiac hypertrophy and dilated cardiomyopathy. The cardiac calcineurin pathway has been suggested to play a role in the development of cardiac hypertrophy in response to a number of physiological and pathological stimuli. Calcineurin, a heterodimeric protein composed of a catalytic and a regulatory subunit, activates the nuclear factor NFATC4 which after translocation to the nucleus associates with the transcription factor GATA4 to activate several cardiac genes involved in hypertrophic response. We have screened the genes encoding the four major components of the heart calcineurin pathway in 95 individuals and identified 27 polymorphisms. These polymorphisms were investigated in 400 selected subjects obtained from a population-based study (LOVE) in relation to echocardiographic parameters. A Gly/Ala substitution at position 160 of the NFATC4 protein (G160A) was associated with left ventricular mass and wall thickness (P=0.02 and 0.006, respectively, GA+AA vs GG), the minor allele (Ala) being associated with lower mean values of these parameters. The other polymorphisms identified by the gene screen were not associated with cardiac phenotypes. For the G160A polymorphism in NFATC4, genotype frequencies were compared between patients with dilated cardiomyopathy and controls obtained from the CARDIGENE Study. Allele A carriers were less frequent in the patient than in the control group (P=0.04). Although the strength of the associations was rather weak, these observations raise the hypothesis that the G160A polymorphism of the NFATC4 gene plays a role in the development of human cardiac hypertrophy.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Molkentin JD, Dorn G : Cytoplasmic signaling pathways that regulate cardiac hypertrophy. Annu Rev Physiol 2001; 63: 391–426.
Balke CW, Shorofsky SR : Alterations in calcium handling in cardiac hypertrophy and heart failure. Cardiovasc Res 1998; 37: 290–299.
Wang MG, Yi H, Guerini D, Klee CB, McBride OW : Calcineurin A alpha (PPP3CA), calcineurin A beta (PPP3CB) and calcineurin B (PPP3R1) are located on human chromosomes 4, 10q21 → q22 and 2p16 → p15 respectively. Cytogenet Cell Genet 1996; 72: 236–241.
Molkentin JD, Lu JR, Antos CL et al: A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 1998; 93: 215–228.
McDonagh TA, Morrison CE, Lawrence A et al: Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population. Lancet 1997; 350: 829–833.
Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, Arveiler D, Rajakangas AM, Pajak A . Myocardial infarction and coronary deaths in the World Health Organization MONICA Project. Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents. Circulation 1994; 90: 583–612.
Tiret L, Mallet C, Poirier O et al: Lack of association between polymorphisms of eight candidate genes and idiopathic dilated cardiomyopathy: the CARDIGENE study. J Am Coll Cardiol 2000; 35: 29–35.
Tiret L, Amouyel P, Rakotovao R, Cambien F, Ducimetiere P : Testing for association between disease and linked marker loci: a log-linear-model analysis. Am J Hum Genet 1991; 48: 926–934.
Schneider S, Roessli D, Excoffier L : Arlequin: a software for population genetics data analysis. Ver 2.000. Genetics and Biometry Lab, Department of Anthropology, University of Geneva, 2000.
Poirier O, Nicaud V, Vionnet N et al: Polymorphism screening of four genes encoding advanced glycation end-product putative receptors. Association study with nephropathy in type 1 diabetic patients. Diabetes 2001; 50: 1214–1218.
Horsley V, Pavlath GK : NFAT: ubiquitous regulator of cell differentiation and adaptation. J Cell Biol 2002; 156: 771–774.
Crabtree GR : Generic signals and specific outcomes: signaling through Ca2+, calcineurin, and NF-AT. Cell 1999; 96: 611–614.
Henikoff S, Henikoff JG : Amino acid substitution matrices from protein blocks. Proc Natl Acad Sci USA 1992; 89: 10915–10919.
Acknowledgements
The Glasgow Heart Scan Study was funded by the Chief Scientist Office of the Scottish Home and Health Department.
Author information
Authors and Affiliations
Corresponding author
Appendix
Appendix
CARDIGENE Project Management Group: M Desnos, Service de Cardiologie, Hôpital Boucicaut, Paris; R Dorent, Service de Chirurgie Cardiaque, Groupe Hospitalier Pitié-Salpêtrière, Paris; M Komajda, Service de Cardiologie, Groupe Hospitalier Pitié-Salpêtrière, Paris; G Roizès, INSERM U249, Montpellier; K Schwartz, INSERM U523, Paris; L Tiret, INSERM U525, Paris, France.
CARDIGENE recruitment centers: CHU Ambroise Paré, Boulogne Billancourt (O Dubourg); CHU Henri Mondor, Créteil (F Paillart); CHR de Lille (A Millaire); Hôpital Louis Pradel, Lyon (X André-Fouët, J Beaune, P Touboul); CHR de Nancy (Y Juillière); CHR de Nantes (J-B Bouhour, N Chedru); CHU Pitié-Salpêtrière, Paris (R Dorent, M Komajda); Hôpital Boucicaut, Paris (M Desnos); Hôpital Bichat, Paris (M-C Aumont); CHR de Strasbourg (A Sacrez).
Rights and permissions
About this article
Cite this article
Poirier, O., Nicaud, V., McDonagh, T. et al. Polymorphisms of genes of the cardiac calcineurin pathway and cardiac hypertrophy. Eur J Hum Genet 11, 659–664 (2003). https://doi.org/10.1038/sj.ejhg.5201023
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.ejhg.5201023
Keywords
This article is cited by
-
New polymorphisms in human MEF2C gene as potential modifier of hypertrophic cardiomyopathy
Molecular Biology Reports (2012)
-
Mutations of the GATA4 and NKX2.5 genes in Chinese pediatric patients with non-familial congenital heart disease
Genetica (2010)
-
The combined impact of metabolic gene polymorphisms on elite endurance athlete status and related phenotypes
Human Genetics (2009)
